FDA 植物药监管再审视：对中药质量监管与证据评价的思考与启示——基于2026 年RFI 与FDA/EMA 联合研讨会

Re-examining FDA Botanical Drug Regulation: Reflections and Implications for TCM Quality Regulation and Evidence Evaluation —Based on the 2026 RFI and the Joint FDA/EMA Workshop

QIAN Zhong-zhi, SONG Zong-hua

China Food Drug Administration . 2026, (10): 18 -27 . DOI: 10.3969/j.issn.1673-5390.2026.10.002